Cancer- the most dreaded combination of alphabets to civilized human is going to get some fight back. Even though there are few drugs available in the market that fights back to cancer, the path to heeling is very painful, thanks to all sort chemotherapy. Almost all these chemical based drugs have one thing in common- devastating side effects. Patients endure the side effects since life is more important than anything else.
Dendreon Corp's Provenge ( Sipuleucel-T ) is rather unique (see how Provenge works)from the perspective of a cancer drug. Unlike chemotherapy Sipuleucel-T teachs the body to fight against cancer causing antigens. So far Provenge has been successfully tested in prostate cancer cases with a noticeable increase in lifespan of a patient. A FDA review committee reviewed the data presented by Dendreon Corp and the agreed to make a favorable recommendation to FDA towards approval of Provenge, the first immunotherapy to treat cancer.
Dendreon Corp is listed at NASDAQ under ticker symbol DNDN. Stock price is expected to jump 50% on Friday.
No comments:
Post a Comment